Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of Lenvima for risk factors of hepatic encephalopathy in unresectable hepatocellular carcinoma
jRCT1080224665Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoint: Risk factors for hepatic encephalopathy under Lenvima treatment. Started May 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1080224665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224665.